Scientific publications and presentations reflect the quality of the innovative research being done by our scientists and clinical collaborators.
Immunomodulation and Pressure-Enabled Regional Immunotherapy
April 2021
Intrahepatic TLR9 activation and immunomodulation compared to systemic infusion
Evaluation of the effect of class C ODN-2395 as TLR9A in controlling LM progression and its impact on the liver MDSC population.
August 2020
Journal for ImmunoTherapy of Cancer
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract No. 9534 Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract No. 9555 Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract 6039 1b/2, Open Label, Multicenter Study of Intratumoral SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870).
January 2019
Oncogene
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
October 2018
Cancer Discovery
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
October 2018
Cancer Discovery
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
October 2016
PNAS
Intratumoral Injection of a CpG Oligonucleotide Reverts Resistance to PD-1 Blockade by Expanding Multifunctional CD8+ T Cells
Drug Delivery
January 2019
Cardiovascular and Interventional Radiology
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
April 2018
Journal of Vascular and Interventional Radiology
Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE
September 2017
PlOS One
Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma
March 2017
SIR Abstract
Surefire Medical’s Infusion Technology Studied for Treatment of Primary Liver Cancer
August 2015
Cardiovascular Interventional Radiology
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
May 2015
Journal of Vascular and Interventional Radiology
The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study